Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States

Jia, X., Zhao, Y., Carrico, J., Brodtkorb, T-H., Mendelsohn, A., Lowry, S., Feldman, S., Armstrong, A., & Wu, JJ. (2018). Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

OCCASIONAL PAPER

Bringing an equity-centered framework to research
OCCASIONAL PAPER

The Preschool Entitlement
OCCASIONAL PAPER

Culturally informed community engagement
Article

Far-right and Jihadi terrorism within the United States